REG - ValiRx PLC - ValiSeek Clinical Development Update <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

19/05/2016 07:09

RNS Number : 6667Y
ValiRx PLC
19 May 2016
ValiRx Plc
("ValiRx" or "the Company")
ValiSeek Clinical Development Update
London, UK, 19 May 2016: ValiRx Plc (AIM: VAL), the life science company with a focus on cancer diagnostics and therapeutics for personalised medicine, is pleased to provide a development update on the clinical development of ValiSeek Limited ("ValiSeek), the joint venture between ValiRx and Tangent Reprofiling Limited, which was formed to progress the novel cancer treatment drug, VAL401, towards Clinical Efficacy trials for the treatment of lung cancer and other oncology indications.
Further to our announcement on 16 July 2015 regarding the commencement of the clinical process for the testing of VAL401 in the treatment of patients, ValiSeek is pleased to confirm the initiation of the clinical manufacturing of the Investigation Medicinal Product ("IMP"), VAL401, for its use in the clinical trial: "A Phase II Study to Assess the Efficacy, Safety and Tolerability of VAL401 in the treatment of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after failure of at least one prior chemotherapeutic regimen".
To date, VAL401 oral capsules, in both 1 mg and 5 mg dose strengths, have been manufactured at a qualified European manufacturer; demonstrating suitability for progression towards a licensed product. The manufacturer is now assembling sufficient quantity of clinical quality VAL401 capsules to commence dosing patients in our Phase 2b trial.
Further stability assays and batch control analysis will be carried out concurrently with the manufacturing process to strengthen the package of information.
*** ENDS ***
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 3008 4416
www.ValiRx.com
Dr Satu Vainikka, Chief Executive
Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications.
Tel: +44 (0) 7879 458 364
tarquin.edwards@ValiRx.com
Mark Treharne, Corporate Development Manager
Tel: +44 (0) 7736 564 686
mark.treharne@ValiRx.com


Cairn Financial Advisers LLP (Nominated Adviser)
Tel: +44 (0) 20 7148 7900
Liam Murray / Avi Robinson



Northland Capital Partners Limited (Broker)
Tel: +44 (0) 20 7382 1100
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Abigail Wayne (Broking)

About ValiSeek
ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company between ValiRx Plc and Tangent Reprofiling Limited, part of the SEEK Group. ValiSeek was formed to progress the drug VAL401 through its remaining preclinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications
About SEEK
Founded in 2004, SEEK (previously known as PepTcell) is privately-owned and funded, with headquarters in London, UK. SEEK brings safe and low costs medicines to the patients as quickly as possible. It does this by modifying existing medicines to improve their efficacy within current label, dose and regime, by changing the indication but keeping the dose and dosing regime the same or by creating a new medicine when the previous options are unavailable.
Additional information about SEEK is available on the Company's website located at www.seekacure.com
About ValiRx Plc 
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed onthe Alternative Investment Market ("AIM") of the London StockExchange in October 2006.
The Company has a pipeline ofother therapeutic drugs, which are currently progressing towards clinicaltrials. The product focus is in the targeted analysis and treatment of cancer,but thetechnologies can be applied to other fields as well, such as neurologyand inflammatory diseases. It actively manages projectswithin its portfolio as a trading company. The ValiRx business model spreads the risks of life science technologydevelopment by minimizing financial exposure andrunning a set of projects todefined commercial endpoints. This maximizes returns to shareholders by adding value at the earlier stages where value increases per investment unit are thegreatest.
The Company operates through the following divisional companies:
1. ValiPharma is the therapeuticsdivision, with two embedded technologies primarily directed at the treatment ofcancers.
2. ValiFinn is the biomarkers anddiagnostic development division. ValiRx acquired through its ValiFinn subsidiary, the complimentary TRAC technology to strengthen the portfolio.
3. ValiSeek is a joint venture between ValiRx and Tangent Reprofiling Ltd to develop Val401 in lung cancer and potentially other indications.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RESBIGDUIXBBGLI